BR0209020A - Composição farmacêutica de polialilamina - Google Patents
Composição farmacêutica de polialilaminaInfo
- Publication number
- BR0209020A BR0209020A BR0209020-1A BR0209020A BR0209020A BR 0209020 A BR0209020 A BR 0209020A BR 0209020 A BR0209020 A BR 0209020A BR 0209020 A BR0209020 A BR 0209020A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- polyallylamine
- polymer
- diluent
- disclosed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
"COMPOSIçãO FARMACêUTICA DE POLIALILAMINA". é descrita uma composição farmacêutica compreendendo um polímero de hidrocloreto de polialilamina estável na qual entre aproximadamente 4% a aproximadamente 12% por peso do polímero é um ânion cloreto e um transportador farmaceuticamente aceitável ou um diluente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28444501P | 2001-04-18 | 2001-04-18 | |
PCT/US2002/011408 WO2002085378A1 (en) | 2001-04-18 | 2002-04-10 | Low salt forms of polyallylamine |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0209020A true BR0209020A (pt) | 2004-08-10 |
Family
ID=23090248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0209020-1A BR0209020A (pt) | 2001-04-18 | 2002-04-10 | Composição farmacêutica de polialilamina |
Country Status (16)
Country | Link |
---|---|
US (2) | US7541024B2 (pt) |
EP (1) | EP1379258B1 (pt) |
JP (2) | JP5170932B2 (pt) |
KR (1) | KR20040018357A (pt) |
CN (1) | CN1290515C (pt) |
AT (1) | ATE331525T1 (pt) |
AU (1) | AU2002252632B2 (pt) |
BR (1) | BR0209020A (pt) |
CA (1) | CA2444587C (pt) |
DE (1) | DE60212819T2 (pt) |
ES (1) | ES2268013T3 (pt) |
HK (1) | HK1058620A1 (pt) |
MX (1) | MXPA03009572A (pt) |
NZ (1) | NZ528829A (pt) |
WO (1) | WO2002085378A1 (pt) |
ZA (2) | ZA200308065B (pt) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
US7220406B2 (en) * | 2002-10-22 | 2007-05-22 | Genzyme Corporation | Method for promoting bone formation |
AU2003263010A1 (en) * | 2003-09-02 | 2005-04-21 | Genzyme Corporation | Method for reducing vascular inflammation |
PT3219312T (pt) | 2004-03-30 | 2019-03-01 | Relypsa Inc | Polímeros de ligação a ião e seus usos |
US20060177415A1 (en) * | 2004-11-01 | 2006-08-10 | Burke Steven K | Once a day formulation for phosphate binders |
US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
JP2009507019A (ja) | 2005-09-02 | 2009-02-19 | ジェンザイム・コーポレーション | リン酸塩を除去する方法およびそれに使用される重合体 |
KR101547925B1 (ko) | 2005-09-15 | 2015-08-27 | 젠자임 코포레이션 | 아민 중합체에 대한 샤셋 제형 |
WO2008005217A2 (en) * | 2006-07-05 | 2008-01-10 | Genzyme Corporation | Iron(ii)-containing treatments for hyperphosphatemia |
US8425887B2 (en) | 2006-09-29 | 2013-04-23 | Genzyme Corporation | Amide dendrimer compositions |
WO2008076242A1 (en) | 2006-12-14 | 2008-06-26 | Genzyme Corporation | Amido-amine polymer compositions |
EP2016947A1 (en) | 2007-07-17 | 2009-01-21 | Chemo Ibérica, S.A. | Novel one step process for preparing cross-linked poly(allylamine) polymers |
AU2009235024A1 (en) * | 2008-04-08 | 2009-10-15 | Usv Limited | Process for preparation of amine polymer salt |
US8404784B2 (en) * | 2008-12-03 | 2013-03-26 | Navinta Llc | Manufacturing process of making polymeric amine salts |
US20120088886A1 (en) * | 2009-06-16 | 2012-04-12 | Watson Pharma Private Limited | Processes for the preparation of sevelamer carbonate |
EP2539380B1 (en) * | 2010-02-24 | 2015-08-19 | Relypsa, Inc. | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants |
KR102633597B1 (ko) | 2013-06-05 | 2024-02-06 | 트리시다, 인크. | 경구 투여를 위한 양성자-결합 중합체 |
CN107428955B (zh) | 2014-12-10 | 2021-09-21 | 特里赛达公司 | 用于口服施用的质子结合聚合物 |
WO2017193064A1 (en) | 2016-05-06 | 2017-11-09 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
JP6792640B2 (ja) | 2016-12-28 | 2020-11-25 | 富士フイルム株式会社 | 窒素原子含有ポリマー又はその塩の乳化液、その製造方法、及び粒子の製造方法 |
JP6992084B2 (ja) | 2017-10-16 | 2022-01-13 | 富士フイルム株式会社 | 高リン血症治療剤 |
CA3079171C (en) | 2017-10-16 | 2023-09-12 | Fujifilm Corporation | Therapeutic agent for hyperphosphatemia and particles |
SG11202003451UA (en) | 2017-11-03 | 2020-05-28 | Tricida Inc | Compositions for and method of treating acid-base disorders |
CN110753217B (zh) * | 2019-10-28 | 2022-03-01 | 黑芝麻智能科技(上海)有限公司 | 色彩平衡方法和装置、车载设备以及存储介质 |
US11572355B2 (en) * | 2020-07-16 | 2023-02-07 | The Board Of Trustees Of The University Of Alabama | Methods for synthesizing vinylidenes and alkenes |
CN112047854B (zh) * | 2020-10-20 | 2021-07-02 | 中国科学院长春应用化学研究所 | 一种n-乙烯基烷基酰胺的制备方法 |
WO2023023938A1 (en) * | 2021-08-24 | 2023-03-02 | Waterstone Pharmaceuticals (Wuhan) Co., Ltd. | Polymers, compositions and methods for treating hyperuricemia |
EP4164659B1 (en) * | 2021-08-24 | 2024-03-27 | Waterstone Pharmaceuticals (Wuhan) Co., Ltd. | Polymers, compositions and methods for treating hyperuricemia |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4222921A (en) * | 1978-06-19 | 1980-09-16 | Monsanto Company | Polyamine/epihalohydrin reaction products |
JPS6090243A (ja) | 1983-10-25 | 1985-05-21 | Nitto Boseki Co Ltd | 小球状モノアリルアミン橋かけ重合体の製造方法 |
CA1220896A (en) | 1983-11-10 | 1987-04-21 | Susumu Harada | Process for producing polymers of monoallylamine |
US4614593A (en) * | 1985-03-28 | 1986-09-30 | Ethyl Corporation | Demulsification of oil-in-water emulsions |
IE914179A1 (en) * | 1990-12-07 | 1992-06-17 | Ici Plc | Nitrogen derivatives |
US5487888A (en) | 1993-05-20 | 1996-01-30 | Geltex, Inc. | Iron-binding polymers for oral administration |
US5607669A (en) * | 1994-06-10 | 1997-03-04 | Geltex Pharmaceuticals, Inc. | Amine polymer sequestrant and method of cholesterol depletion |
US5624963A (en) | 1993-06-02 | 1997-04-29 | Geltex Pharmaceuticals, Inc. | Process for removing bile salts from a patient and compositions therefor |
US5900475A (en) | 1994-06-10 | 1999-05-04 | Geltex Pharmaceuticals, Inc. | Hydrophobic sequestrant for cholesterol depletion |
US5618530A (en) | 1994-06-10 | 1997-04-08 | Geltex Pharmaceuticals, Inc. | Hydrophobic amine polymer sequestrant and method of cholesterol depletion |
US5703188A (en) | 1993-06-02 | 1997-12-30 | Geltex Pharmaceuticals, Inc. | Process for removing bile salts from a patient and compositions therefor |
US5496545A (en) | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
US5667775A (en) | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
TW474813B (en) | 1994-06-10 | 2002-02-01 | Geltex Pharma Inc | Alkylated composition for removing bile salts from a patient |
WO1996021454A1 (en) * | 1995-01-12 | 1996-07-18 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
US6203785B1 (en) | 1996-12-30 | 2001-03-20 | Geltex Pharmaceuticals, Inc. | Poly(diallylamine)-based bile acid sequestrants |
US5925379A (en) | 1997-03-27 | 1999-07-20 | Geltex Pharmaceuticals, Inc. | Interpenetrating polymer networks for sequestration of bile acids |
TW592727B (en) | 1997-04-04 | 2004-06-21 | Chugai Pharmaceutical Co Ltd | Phosphate-binding polymer preparations |
JP2003183168A (ja) * | 1997-04-04 | 2003-07-03 | Chugai Pharmaceut Co Ltd | リン酸結合性ポリマー含有製剤 |
US6423754B1 (en) * | 1997-06-18 | 2002-07-23 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with polyallylamine polymers |
US5985938A (en) | 1997-11-05 | 1999-11-16 | Geltex Pharmaceuticals, Inc. | Method for reducing oxalate |
US6726905B1 (en) | 1997-11-05 | 2004-04-27 | Genzyme Corporation | Poly (diallylamines)-based phosphate binders |
US6083497A (en) | 1997-11-05 | 2000-07-04 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers |
AU2682499A (en) | 1998-02-17 | 1999-08-30 | Dimitri R. Kioussis | Anion binding polymers and the use thereof |
TW568788B (en) * | 1998-10-12 | 2004-01-01 | Chugai Pharmaceutical Co Ltd | Polymer combining with phosphoric acid and preparation containing the same |
US6180754B1 (en) * | 1999-09-03 | 2001-01-30 | The Dow Chemical Company | Process for producing cross-linked polyallylamine polymer |
US6733780B1 (en) * | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
-
2002
- 2002-04-10 BR BR0209020-1A patent/BR0209020A/pt not_active IP Right Cessation
- 2002-04-10 JP JP2002582951A patent/JP5170932B2/ja not_active Expired - Fee Related
- 2002-04-10 AT AT02721716T patent/ATE331525T1/de active
- 2002-04-10 EP EP02721716A patent/EP1379258B1/en not_active Expired - Lifetime
- 2002-04-10 MX MXPA03009572A patent/MXPA03009572A/es active IP Right Grant
- 2002-04-10 AU AU2002252632A patent/AU2002252632B2/en not_active Ceased
- 2002-04-10 NZ NZ528829A patent/NZ528829A/en unknown
- 2002-04-10 DE DE60212819T patent/DE60212819T2/de not_active Expired - Lifetime
- 2002-04-10 ES ES02721716T patent/ES2268013T3/es not_active Expired - Lifetime
- 2002-04-10 WO PCT/US2002/011408 patent/WO2002085378A1/en active IP Right Grant
- 2002-04-10 CN CNB02808487XA patent/CN1290515C/zh not_active Expired - Fee Related
- 2002-04-10 CA CA002444587A patent/CA2444587C/en not_active Expired - Fee Related
- 2002-04-10 KR KR10-2003-7013677A patent/KR20040018357A/ko not_active Application Discontinuation
- 2002-04-17 US US10/125,684 patent/US7541024B2/en not_active Expired - Fee Related
-
2003
- 2003-10-16 ZA ZA200308065A patent/ZA200308065B/en unknown
- 2003-10-16 ZA ZA200308063A patent/ZA200308063B/en unknown
-
2004
- 2004-02-25 HK HK04101375A patent/HK1058620A1/xx not_active IP Right Cessation
-
2009
- 2009-04-21 US US12/427,127 patent/US8377428B2/en not_active Expired - Fee Related
-
2010
- 2010-02-01 JP JP2010020592A patent/JP5243466B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1290515C (zh) | 2006-12-20 |
CA2444587C (en) | 2008-10-21 |
CN1503676A (zh) | 2004-06-09 |
MXPA03009572A (es) | 2004-02-12 |
WO2002085378A1 (en) | 2002-10-31 |
JP2004526777A (ja) | 2004-09-02 |
AU2002252632B2 (en) | 2004-09-23 |
EP1379258B1 (en) | 2006-06-28 |
KR20040018357A (ko) | 2004-03-03 |
ZA200308063B (en) | 2005-01-17 |
US7541024B2 (en) | 2009-06-02 |
NZ528829A (en) | 2006-06-30 |
CA2444587A1 (en) | 2002-10-31 |
JP2010111704A (ja) | 2010-05-20 |
ATE331525T1 (de) | 2006-07-15 |
US20100068167A1 (en) | 2010-03-18 |
EP1379258A1 (en) | 2004-01-14 |
HK1058620A1 (en) | 2004-05-28 |
DE60212819D1 (de) | 2006-08-10 |
ZA200308065B (en) | 2004-09-14 |
DE60212819T2 (de) | 2006-11-23 |
JP5243466B2 (ja) | 2013-07-24 |
US20020159968A1 (en) | 2002-10-31 |
US8377428B2 (en) | 2013-02-19 |
ES2268013T3 (es) | 2007-03-16 |
JP5170932B2 (ja) | 2013-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0209020A (pt) | Composição farmacêutica de polialilamina | |
PL350456A1 (en) | N−cyanomethylamides as protease inhibitors | |
GEP20074208B (en) | Substituted amides active at the cannabinoid-1 receptor | |
LU92315I2 (fr) | Combinaison comprenant aliskiren, ou un de ses sels pharmaceutiquement acceptable, et amlodipine, ouun de ses sels pharmaceutiquement acceptable | |
DE602004024375D1 (de) | Carboxamidderivate | |
PT1073470E (pt) | Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos | |
MXPA02012712A (es) | N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas. | |
HUP0104709A2 (hu) | Eritropoietin vagy eritropoietrinszármazékok alkalmazása agyi iszkémiák kezelésére használható gyógyszer előállítására | |
SE0101932D0 (sv) | Pharmaceutical combinations | |
EP1619180A4 (en) | CASR ANTAGONIST | |
ATE303384T1 (de) | 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren | |
SE0102440D0 (sv) | New compound | |
SE0102055D0 (sv) | New Compounds | |
BR0012696A (pt) | Composição oftálmica | |
IL157540A0 (en) | N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof | |
MXPA04001419A (es) | Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson. | |
TNSN04034A1 (en) | Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof | |
SE9802209D0 (sv) | Novel compounds | |
SE0001916D0 (sv) | Novel formulation | |
ES2197781A1 (es) | Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno. | |
WO2004048381A3 (en) | Pyrazoloazepine compounds as pharmaceutical agents | |
TW200510370A (en) | Urea derivatives | |
EP1411956B8 (en) | Use of oversulfated polysaccharides as inhibitors of hiv | |
MXPA03010259A (es) | Nuevos derivados de 5-tio-ss-d-xilopiranosida, procedimiento de preparacion, composiciones farmaceuticas que los contienen y el uso terapeutico de los mismos. | |
IL159493A0 (en) | Pharmaceutical formulation containing an ltb4 antagonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: GENZYME CORPORATION (US) Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 018080029522/SP DE 14/05/2008. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A,6A E 7A ANUIDADES |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009. |